Investment Analysts’ Weekly Ratings Changes for Royalty Pharma (RPRX)

Royalty Pharma (NASDAQ: RPRX) recently received a number of ratings updates from brokerages and research firms:

• 8/8/2026 – Royalty Pharma was downgraded by Wall Street Zen from “strong-buy” to “buy”.
• 8/7/2026 – Royalty Pharma had its price target raised by JPMorgan Chase & Co. from $58.00 to $62.00. They now have an “overweight” rating on the stock.
• 8/6/2026 – Royalty Pharma had its “buy” rating reaffirmed by The Goldman Sachs Group, Inc.. They now have a $66.00 price target on the stock.
• 8/6/2026 – Royalty Pharma had its “overweight” rating reaffirmed by Morgan Stanley. They now have a $65.00 price target on the stock.
• 8/5/2026 – Royalty Pharma had its “buy” rating reaffirmed by Bank of America Corporation.
• 7/13/2026 – Royalty Pharma had its price target raised by TD Cowen from $50.00 to $65.00. They now have a “buy” rating on the stock.

Royalty Pharma Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Investors of record on Friday, August 14th will be given a dividend of $0.235 per share. This represents a $0.94 dividend on an annualized basis and a yield of 1.6%. The ex-dividend date of this dividend is Friday, August 14th. Royalty Pharma’s dividend payout ratio is 64.83%.

Insider Buying and Selling at Royalty Pharma

In related news, CFO Terrance P. Coyne sold 64,399 shares of the stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $53.98, for a total value of $3,476,258.02. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Gregory Norden sold 3,045 shares of the company’s stock in a transaction dated Thursday, May 14th. The stock was sold at an average price of $53.00, for a total value of $161,385.00. Following the completion of the sale, the director directly owned 191,803 shares of the company’s stock, valued at $10,165,559. The trade was a 1.56% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 393,009 shares of company stock valued at $21,601,827. 18.84% of the stock is currently owned by corporate insiders.

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.